Validation of suitable endogenous control genes for expression studies of miRNA in prostate cancer tissues.
INTRODUCTION
MicroRNAs (miRNAs) belong to a class of small RNAs discovered in 1993 by Victor Ambros and colleagues in a genetic screen of Caenorhabditis elegans. 1 Later, miRNAs have been found in a diverse range of species including plants, animals and DNA viruses. MiRNAs play a key role in several biological processes including development, cell proliferation, differentiation and apoptosis. [1] [2] [3] [4] Initially northern blots and microarrays were used for miRNA expression studies, but as qPCR protocols for quantitative miRNA expression studies were developed, these protocols have become the most widely used. Compared to other methods, such as northern blot, qPCR has some advantages because of its sensitivity and the low template requirements. In the current protocol, multiplex stem-loop primers are used in qPCR for conversion of mature miRNAs into cDNA, which allows for the simultaneous transcription of all miRNAs during a PCR. 5 When a qPCR is performed, technical variations between the reactions have to be corrected for.
One way to check for such causes of variation is to incorporate an endogenous control gene in the experiment, which can be used as a reference to normalize gene expression data sets. 5 It is important that the control gene is carefully chosen since it has been proven that depending on which tissue is used, the expression of even the most commonly used housekeeping genes like ACTB (Actin Beta) and GAPDH (Glycerylaldehyd 3-phospahte dehydrogenase) is not always stable between samples. Thus, since no universal endogenous control exists, it is recommended to test for the most suitable control gene in the tissues used. 6 In this study, six different endogenous control genes for studies of miRNA expression were used.
The endogenous control genes RNU48, RNU44, RNU43, RNU24 and RNU6B belong to a class of small non-coding RNAs, small nucleolar RNAs, while MammU6 (U6) belongs to the class small nuclear RNAs. [6] [7] The samples used for the test of stability of the control genes were formalin fixed paraffin embedded prostate cancer tissue material.
MATERIALS AND METHODS

Patient material
Patients were recruited from the population-based Swedish Watchful Waiting cohort, 8 consisting of 1256 men with localized prostate cancer. These men had symptoms of benign prostatic hyperplasia (lower urinary tract symptoms) and were subsequently diagnosed with prostate cancer through transurethral resection (TUR-P). All men in this study were determined at the time of diagnosis to have clinical stage T1 a or T1 b, Mx, and Nx, according to the 2002 American Joint Committee on
Cancer staging system TNM. 9 The prospective follow-up time is now up to 30 years. This study includes samples from men who were diagnosed at the University Hospital in Örebro (1977) (1978) (1979) (1980) (1981) (1982) (1983) (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) and at four centers in the southeast region of Sweden: Kalmar, Norrköping, Linköping, and
Jönköping (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) . The study was approved by the ethical committee in the Uppsala-Örebro region. The material consisted of formalin fixed paraffin embedded (FFPE) tissues from 19 cases and the adjacent normal tissue in each individual. We collected cases randomly within each category of Gleason score (4-6, 7, 8-10) to get an equal distribution of histological differentiation.
MiRNA qPCR arrays
In this study the TaqMan MicroRNA assays plus 20 control assays per card, which enables quantification of totally 667 unique human miRNAs. Card A contains miRNAs that tend to be functionally defined, and are broadly and/or highly expressed. The miRNAs in card B are less extensively studied and are narrowly expressed and/or expressed at low levels, and are usually not functionally defined.
Endogenous controls
The six endogenous controls investigated in this study were MammU6 (small nuclear RNA), RNU48, RNU44, RNU43, RNU24 and RNU6B (small nucleolar RNAs). [6] [7] Three of these controls were found on both cards, A and B, while the other three were only found in card B. On card A, only MammU6 was found in four replicates while the other two controls appeared just once. On card B, all six controls were found in four replicates (Table 1) .
RNA extraction and cDNA preparation
Malignant and surrounding normal areas were marked by a pathologist on the paraffin blocks prior to punching out 3-4 cores (ø 0.6 mm) using the Tissue Micro Array equipment (Pathology devices, Westminster, USA). The cores were deparaffinazed in a standard protocol using xylene and alcohols. The Recover All Total Nucleic Acid Isolation Kit (Ambion) optimized for FFPE samples was used to extract total RNA. A reverse transcription reaction using 4-10 ng of total RNA was performed using TaqMan ® MicroRNA reverse transcription kit and Megaplex ™ RT primers, human pool v2.0 (Applied Biosystems) and the RT-product was then pre-amplified using Megaplex ™ PreAmp primers and Taqman® Preamp master mix (Applied Biosystems).
Quantitative PCR
The pre-amplified cDNA samples were diluted in a 0. 
Calculations of stability of endogenous controls and statistical tests
The stability of the endogenous controls was evaluated using NormFinder and BestKeeper software applications. 10 For statistical evaluations of Ct values, data were analyzed for differences among replicates by oneway ANOVA (Table 1 ). Student's t-test was performed for comparisons of normal and malignant tissues and a paired samples correlation was performed in the same analysis (PASW Statistics 18, SPSS Inc, Chicago, USA). In both tests the null hypotheses were assuming no differences between replicates (ANOVA), and no differences between tissue types (t-test).
RESULTS
To check for differences among replicates in the six endogenous controls, a one-way ANOVA analysis was performed. There were no significant differences (p>0.0 5) among replicates in any of the endogenous controls (Table 1) . Thus, mean Ct values were used for further evaluation of the stability of the endogenous controls included in the study by NormFinder and BestKeeper.
NormFinder returns a stability value and standard error for each endogenous control gene and
BestKeeper determines the standard deviation and coefficient of variance (CV). To ease the comparison between the results from the two software applications, standard error from
NormFinder was transformed to standard deviation (Table 1) .
Using both NormFinder and BestKeeper we were able to identify RNU24 and RNU44 as the two most stable control genes and with the exception of the order of MammU6 and RNU48, the concordance between the two tests was very good. The Student´s t-tests revealed significant differences between malignant and normal samples in two of the endogenous controls investigated, RNU43 and RNU44 (Table 1) .
To visualize the variation in expression of control genes, raw Ct values for each tissue sample was plotted in a graph ( Figure 1 ). There are four peaks in the graph that represent deviations in expression in the least stable endogenous control RNU6B and two peaks for the second least stable control, RNU43.
DISCUSSION
Before analyzing large scale expression data, normalization is performed to minimize the variation due to technical reasons, and to increase the expression accuracy of biologically meaningful data.
When analyzing data from qPCR experiments, the number of normalization methods is limited due to the small number of target genes investigated, which is not suited for the population-based normalization approaches that are commonly used in microarray studies. Therefore, normalization of qPCR data is usually dependent on using endogenous control genes as a reference for normal expression. 12 When considering endogenous controls for miRNA expression studies, it is important that the chosen controls share similar properties with miRNAs. Properties to be considered include tissueindependent RNA stability and nucleotide size, but also whether the controls can be used in the miRNA assay design. Other small non-coding RNAs, not belonging to the miRNA class, like nuclear RNAs and nucleolar RNAs have a high abundance, are stably expressed, and are similar in size compared to miRNAs. In addition it is unlikely that these non-coding RNAs are involved in pathways that regulate miRNAs, and therefore they fulfill the prerequisites for endogenous controls in miRNA studies. 6 In this study, we investigated six different endogenous controls in formalin fixed paraffin embedded prostate tissue from the Swedish Watchful Waiting cohort. The six controls were present in the TaqMan ® MicroRNA Array Set v2.0, where MammU6, RNU48, and RNU44 were present in both cards and RNU43, RNU24, and RNU6B were present only in card B. Thus, the endogenous controls were represented by different numbers of technical replicates (Table 1 ). We applied a oneway ANOVA on raw Ct values from the endogenous controls and this test revealed that no significant differences existed between replicates in any of the endogenous controls. Thus, we could safely use mean values for the replicates in the subsequent stability tests. Several software applications for assessing the stability of candidate control genes are available and in this study two of these software applications were used; NormFinder and BestKeeper.
In BestKeeper the value (CV) used to determine the stability value of a specific control is actually the coefficient of variation (C v ) for the same gene, multiplied with 100 (s/m)*100). NormFinder calculates a stability value defined as the absolute mean value plus one SD, and it is calculated using the intergroup variation values from the control genes. GeNorm, a third software application used to calculate stability measures of endogenous controls, not used in this study, defines the stability value as the arithmetic mean of all pair wise comparisons. 13 Both test systems used in this study, NormFinder and BestKeeper, recognized RNU24, followed by RNU44, as the two most stable controls. The third best endogenous control differed between the two software applications, as RNU48 was identified by NormFinder and MammU6 by BestKeeper.
The slight difference in standard deviation between the tests may be explained by the variation in the number of input values used in the analysis. In NormFinder, delta Ct values were used (19 comparisons) whereas in BestKeeper, 38 raw Ct values were used in the calculations. According to the results from the present study we can conclude that both RNU24 and RNU44 would be suitable control genes for miRNA expression studies in prostate tissues since we could pinpoint these as the most stable control genes independently of the software application used. However, we propose that RNU24 is the best of these control genes due to the fact that the t-test, which actually verified the NormFinder results, revealed no significant difference between normal and malignant samples, which was not the case with RNU44. In addition, the slightly lower standard deviation for RNU24, compared to RNU44, further supports this choice ( Table 1 , Figure 1 ). The variation of expression of the control genes across different tissue samples illustrated in Figure 1 clearly supports the fact that RNU43 and RNU6B are not stable control genes, due to the high peaks in expression in some samples compared to the other samples and controls. Pearson correlation coefficient was calculated for all endogenous controls and a positive correlation between normal and malignant tissues was revealed in all comparisons.
Only a few studies concerning validation of endogenous controls for miRNA expression studies have been published. The fact that the controls used in these studies are not consistently the same as in our study, hamper proper comparisons with our results. Five of the control genes in our study, together with 13 other control genes, have previously been studied in different types of human leukemia samples and normal bone marrow samples using geNorm. The results were inconclusive since other control genes were considered to be stably expressed in the different tissues investigated, although RNU24 was among the most stable in all of them. The expression stability of RNU48 has previously been investigated in human breast cancer tissue as well as in prostate cancer tissue using both NormFinder and geNorm 5, 15 and was found to be among the three most stable control genes in both types of tissue. The expression stability of RNU6B has also been investigated in two studies in human lung tumor tissue, human breast cancer tissue and canine lymphoma using both NormFinder and geNorm. The results in these studies support our own results as the results were similar to ours, concluding that RNU6B is not a stable control gene. 12, 5, 16 So, from the results of the present study, we identified RNU24 as the most stable control gene.
However, it could not be entirely verified from other studies mostly due to lack of corresponding data. The differences from our result between the studies might be due to differences in the amount of biological and technical replicates but may also be due to the stability analysis, since different software applications was used for this purpose (geNorm vs. NormFinder and BestKeeper). The result also reveals the need for a systematic evaluation of the performance of different applications in order to optimize them.
In a recently published study of miRNA profiling in prostate cancer, a miRNA gene has been used as control for normalization. This miRNA, hsa-mir130b, was the most stable miRNA in that data set, and thus more stable then the endogenous control gene RNU6B. 17 As the miRNA hsa-mir 130b was included in our data set, the expression stability for this miRNA could be studied. We found that hsa-mir 130b was less stable than all of the control genes included in the present study (data not shown), suggesting that hsa-mir 130b is a poor candidate control gene.
In summary, this study investigated six endogenous candidate control genes for miRNA expression studies in prostate tissues. The controls were tested for stability across normal and malignant tissue, 
